Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference37 articles.
1. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials;Lancet Oncol,2018
2. Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay;Prat;Clin Cancer Res,2016
3. 2019: a brief summary of the consensus discussion on the optimal primary breast cancer treatment;Balic;Breast Care (Basel),2019
4. Breast cancer;Harbeck;Lancet,2017
5. Biomarker alteration after neoadjuvant endocrine therapy or chemotherapy in estrogen receptor-positive breast cancer;Long;Life (Basel),2022
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer;Current Treatment Options in Oncology;2024-08-17
2. HER2-Low Breast Cancer: Now and in the Future;Cancer Research and Treatment;2024-07-15
3. Evolution and prognostic significance of HER-2 conversion from primary to residual disease in HER-2 negative patients with breast cancer after neoadjuvant chemotherapy;American Journal of Cancer Research;2024
4. HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low category;Human Pathology;2023-12
5. Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer;European Journal of Cancer;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3